Market reaction and headline findings
Novo Nordisk shares dropped roughly 10% on Friday after the Danish drugmaker announced that ziltivekimab, its investigational IL-6 inhibitor, failed to lower cardiovascular risk in a late-stage trial. The company said the Phase 3 ZEUS study found no statistically significant reduction in major adverse cardiovascular events, reporting a hazard ratio of 0.99 with a 95% confidence interval of 0.88 to 1.11 compared with placebo.
What the ZEUS trial tested
The double-blind, placebo-controlled ZEUS trial enrolled more than 6,300 patients who had atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and evidence of systemic inflammation. Investigators evaluated a once-monthly 15 mg dose of ziltivekimab against placebo with the primary endpoint defined as MACE - cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.
Although ziltivekimab achieved its intended biological effects - inhibiting the IL-6 pathway and producing expected reductions in free IL-6 and high-sensitivity C-reactive protein - that biomarker activity did not translate into fewer major cardiovascular events.
"Despite not achieving the hoped-for MACE benefit, this study provides vital scientific evidence that will help inform our ongoing cardiovascular research," said Martin Holst Lange, Executive Vice President and Chief Scientific Officer at Novo Nordisk.
Safety and follow-up trials
Overall rates of adverse events and serious adverse events were similar between the ziltivekimab and placebo arms, and there was no difference in all-cause mortality. The company did note a higher incidence of serious infections among patients receiving ziltivekimab.
Two additional cardiovascular studies of ziltivekimab, focused on heart failure and on patients after acute heart attack, will continue as planned, with results expected in the first half of 2027.
Financial implications
Novo Nordisk said the ZEUS outcome will not alter its previously announced 2026 adjusted operating profit guidance. However, the company confirmed it will take a non-cash impairment charge in the third quarter of 2026 related to the trial results.
Wall Street reaction and analyst views
Analysts framed the readout as a negative for Novo Nordisk’s research trajectory. UBS analyst Matthew Weston labeled the trial outcome "NEGATIVE," noting UBS had modeled 60% of ziltivekimab’s $3 billion peak sales and that the program accounted for about 1.7% of Novo Nordisk’s net present value in prior estimates. Weston warned that market reaction is likely to be two to three times larger than the narrow NPV impact and flagged two knock-on effects: increasing R&D pressure and limiting the opportunity to develop cardiovascular therapies into a material secondary growth engine alongside the company’s metabolic franchise.
Mizuho analyst Jared Holz described the early look at the ZEUS data as a "disappointment," saying the readout could damp investor sentiment across Novo Nordisk’s wider pipeline. Holz observed that expectations had been shifting toward optimism on efficacy and concern about tolerability, but the result reversed that dynamic - safety appeared acceptable, yet the lack of statistically significant benefit leaves the program materially impaired for shareholders today.
Holz added that while other IL-6 cardiovascular trials remain ongoing, he expects investors to heavily discount those programs in the near term until more readouts approach, roughly a year from now. He also suggested the setback could increase pressure on management to pursue more substantive mergers and acquisitions to broaden therapeutic capabilities beyond assets tied to obesity.
Shares of industry peers cited by analysts also moved on the news, with comparable companies GLUE and BIOA experiencing pre-market weakness following the ZEUS announcement.
Near-term stock dynamics
Some analysts noted that Novo Nordisk is positioned to face upcoming corporate catalysts. In particular, strong early performance of the Wegovy oral product was called out as a potential support for the stock into the company’s Q3 earnings report scheduled for next Wednesday; that dynamic could draw buying interest amid the current weakness.
Bottom line
The ZEUS Phase 3 result leaves ziltivekimab without a demonstrated reduction in MACE despite clear biomarker effects, prompting a market sell-off and renewed scrutiny of Novo Nordisk’s cardiovascular ambitions. While financial guidance for 2026 remains intact, the company will record a Q3 2026 non-cash impairment and must now weigh clinical and strategic options as follow-on studies continue.